AFM-24I is under clinical development by Affimed and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect AFM-24I’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AFM-24I Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

AFM-24I overview

AFM-24I is under development for the treatment of solid tumors including but not limited to colorectal cancer, head and neck cancer squamous cell carcinoma, lung cancer, gastroesophageal (GE) junction carcinomas, biliary tract cancer, hepatocellular carcinoma and metastatic colorectal cancer, gastric cancer, esophageal cancer, pancreatic cancer, head and neck cancer, breast cancer, ovarian cancer, cervical cancer, urothelial cancer, renal cell carcinoma, and glioblastoma multiforme. The drug candidate is a bi-specific monoclonal antibody act by targeting NK-cell via its CD16A receptor and tumor-specific wild type epidermal growth factor receptor (EGFR). The drug candidate is developed based on Redirected Optimized Cell Killing (ROCK) platform.

Affimed overview

Affimed, formerly Affimed Therapeutics, a subsidiary of Affimed NV, discovers and develops immunotherapies to treat hematologic cancers and solid tumors. The company is investigating AFM13, an innate cell engager, for the treatment of Peripheral T cell lymphoma, transformed mycosis fungoides, CD30-positive T cell lymphoma and Hodgkin’s lymphoma; AFM24, against solid tumors; AFM-26, targeting B-cell maturation antigen to treat multiple myeloma. It generates multi-specific antibodies to kill tumor cells and treat cancers through its ROCK platform technology. The company works in partnership with Amphivena Therapeutics Inc, Merck & Co Inc, Genentech Inc, AbCheck SRO and other companies to advance its pipeline. Affimed is headquartered in Heidelberg, Baden-Wurttemberg, Germany

Quick View AFM-24I LOA Data

Report Segments
  • Innovator
Drug Name
  • AFM-24I
Administration Pathway
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: Affimed
  • Originator: Affimed
Highest Development Stage
  • Phase II


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.